Analysts expect Cooper Companies Inc (NYSE:COO) to post sales of $679.15 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Cooper Companies' earnings, with estimates ranging from $677.30 million to $680.70 million. Cooper Companies posted sales of $691.60 million in the same quarter last year, which suggests a negative year-over-year growth rate of 1.8%. The firm is expected to announce its next quarterly earnings report on Thursday, December 3rd.
On average, analysts expect that Cooper Companies will report full year sales of $2.43 billion for the current financial year. For the next year, analysts anticipate that the company will post sales of $2.76 billion, with estimates ranging from $2.70 billion to $2.81 billion. Zacks Investment Research's sales calculations are an average based on a survey of analysts that cover Cooper Companies.
Cooper Companies (NYSE:COO) last issued its quarterly earnings results on Thursday, September 3rd. The medical device company reported $2.28 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.58 by $0.70. The company had revenue of $578.20 million during the quarter, compared to the consensus estimate of $536.11 million. Cooper Companies had a return on equity of 13.19% and a net margin of 11.40%. Cooper Companies's revenue was down 14.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.23 EPS.
A number of equities research analysts have issued reports on COO shares. TheStreet upgraded shares of Cooper Companies from a "c+" rating to a "b-" rating in a research report on Thursday, September 3rd. Raymond James raised their price target on shares of Cooper Companies from $330.00 to $375.00 and gave the company an "outperform" rating in a report on Thursday, September 17th. JPMorgan Chase & Co. raised their price target on shares of Cooper Companies from $285.00 to $315.00 and gave the company a "neutral" rating in a report on Friday, September 4th. KeyCorp raised their price target on shares of Cooper Companies from $330.00 to $349.00 and gave the company an "overweight" rating in a report on Friday, September 4th. Finally, Robert W. Baird downgraded shares of Cooper Companies from an "outperform" rating to a "neutral" rating and cut their price target for the company from $335.00 to $291.00 in a report on Monday, July 6th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Cooper Companies currently has a consensus rating of "Buy" and a consensus price target of $338.77.
In related news, CEO Robert D. Auerbach sold 2,538 shares of the business's stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $350.00, for a total transaction of $888,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jody S. Lindell sold 6,500 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $338.69, for a total transaction of $2,201,485.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,038 shares of company stock valued at $3,438,325. 1.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of COO. Vestmark Advisory Solutions Inc. raised its holdings in Cooper Companies by 15.6% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 4,943 shares of the medical device company's stock worth $1,666,000 after purchasing an additional 666 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of Cooper Companies by 19.0% during the 3rd quarter. Louisiana State Employees Retirement System now owns 2,500 shares of the medical device company's stock worth $843,000 after buying an additional 400 shares during the period. IBM Retirement Fund grew its position in Cooper Companies by 39.0% in the 3rd quarter. IBM Retirement Fund now owns 1,582 shares of the medical device company's stock valued at $533,000 after purchasing an additional 444 shares during the period. Spearhead Capital Advisors LLC acquired a new stake in Cooper Companies in the 3rd quarter valued at $203,000. Finally, IFM Investors Pty Ltd grew its position in Cooper Companies by 13.2% in the 3rd quarter. IFM Investors Pty Ltd now owns 4,284 shares of the medical device company's stock valued at $1,444,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 88.84% of the company's stock.
Cooper Companies stock opened at $348.42 on Tuesday. The company has a 50 day moving average price of $336.85 and a 200 day moving average price of $305.88. Cooper Companies has a 52 week low of $236.68 and a 52 week high of $365.68. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.64 and a current ratio of 1.17. The firm has a market capitalization of $18.58 billion, a price-to-earnings ratio of 62.33, a P/E/G ratio of 3.74 and a beta of 0.82.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Read More: Stochastic Momentum Index (SMI)
Get a free copy of the Zacks research report on Cooper Companies (COO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Stocks to Help You Profit Off the Coronavirus PPE Boom
Every major global event brings with it changes to our national lexicon. Before the Covid-19 pandemic, few Americans knew what the initials PPE stood for. Today, virtually anyone knows that PPE stands for personal protective equipment.
At the onset of the mitigation policies, the goal of flattening the curve was being done to prevent our health care system from becoming overwhelmed. Part of that concern stemmed from a shortage of personal protective equipment. These are the masks, gloves, goggles and gowns that help protect medical workers against viral or bacterial infections.
As the novel coronavirus became labeled a global pandemic, the global mantra became to “flatten the curve” in an effort to prevent our healthcare system from being overwhelmed.
The United States is being referred to as being on a war time footing. Manufacturers that were already producing PPE have significantly ramped up capacity. And many companies are converting their excess manufacturing capacity to produce personal protective equipment.
In fairness, this may only be a reason for some of these companies to “keep the lights on” right now. But many of these companies have a good story to tell. And it’s that story that can make them solid investments in the future.
View the "6 Stocks to Help You Profit Off the Coronavirus PPE Boom".